Current stock page

Financial Data

IMNM Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

IMNMImmunome, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

BearishEdge 8/10
$18.77+$0.07 (+0.37%)

Latest quote

  • Momentum
    45
  • Value
    —
  • Quality
    52
  • Risk resilience
    47
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$4.02M$2.93M$2.74M
Gross Profit$0$0-$753K$0-$49.19M$3.3M$2.93M$2.74M
Operating Income-$90.36M-$78.14M-$59.33M-$72.86M-$60.14M-$46.48M-$44.64M-$82.97M
Net Income-$85.78M-$73.13M-$53.84M-$69.9M-$57.46M-$43.4M-$41.64M-$80.25M
EPS-$0.76-$0.65-$0.48-$0.76-$0.65-$0.5-$0.52-$1.28
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$60.75M-$61.69M-$58.64M-$47.95M-$40.51M-$49.4M-$53.06M-$42.06M
Capital Expenditure-$489K-$2.18M-$3M-$4M-$1.12M-$905K-$3.67M-$1.38M
Free Cash Flow-$61.24M-$63.87M-$61.64M-$51.95M-$41.63M-$50.31M-$56.72M-$43.44M
Net Cash Provided By Operating Activities-$60.75M-$61.69M-$58.64M-$47.95M-$40.51M-$49.4M-$53.06M-$42.06M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$505.53M$565.38M$619.79M$683.19M$299.38M$296.29M$342.69M$240.24M
Total Debt$11.39M$4.59M$3.69M$3.86M$4.01M$4.14M$4.77M$4.83M
Cash And Cash Equivalents$212.84M$217.71M$582.69M$653.48M$272.64M$143.88M$257.61M$143.35M
Total Liabilities$51.22M$40.3M$31.11M$48.85M$35.46M$27.02M$35.57M$59.08M
Total Stockholders Equity$454.3M$525.08M$588.69M$634.34M$263.92M$269.27M$307.13M$181.17M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio4.845.664.362.975.173.382.052.97
P/S ratio————————
Debt To Equity0.030.010.010.010.020.020.020.03
Free Cash Flow Yield-10.86%-7.37%-8.01%-10.66%-14.09%-20.45%-25.63%-22.00%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio4.845.664.362.975.173.382.052.97
P/S ratio————————
Return On Equity-62.22%-48.43%-38.15%-33.48%-84.40%-78.87%-66.78%-161.71%
Debt To Equity0.030.010.010.010.020.020.020.03

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-7.08x
Pb4.69x
EPS Growth Yoy-16.92%
Gross Margin0.00%
Operating Margin0.00%
ROE-51.33%
ROIC-64.57%
Debt To Equity0.03
FCF Yield-10.77%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$18.77
Volume951,077
RSI (14)46.9
MACD-0.37
MACD signal-0.56
MACD histogram0.2
ADX (14)24.1
SMA (50)$20.65
SMA (200)$22.21
ATR (14)$1.25
Historical volatility (annualized)61.42%
Volume (20-day average)1.52M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score47/100
Beta1.47
Annual volatility60.72%
Max Drawdown-44.78%
Sharpe Ratio0.45
VaR (95%, 1-day)-5.64%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

IMNM Financial Data FAQ

What is Immunome, Inc.'s revenue?

Immunome, Inc.'s revenue is one of the core financial data points for IMNM. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Immunome, Inc.'s revenue growing?

Revenue growth shows whether Immunome, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is IMNM's EPS?

IMNM's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Immunome, Inc.'s net income?

Immunome, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Immunome, Inc. generate?

Free cash flow shows how much cash Immunome, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Immunome, Inc. have?

Cash and debt help frame IMNM's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.